High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, DeCook AC, Enders F, Lindor KD.
Imam MH, et al.
Aliment Pharmacol Ther. 2011 Nov;34(10):1185-92. doi: 10.1111/j.1365-2036.2011.04863.x. Epub 2011 Sep 29.
Aliment Pharmacol Ther. 2011.
PMID: 21957881
Free PMC article.